For the quarter ending 2025-09-30, TIL had -$1,732K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -13,587 | -49,594 |
| Stock-based compensation | 1,768 | 5,319 |
| Non-cash lease expense | 71 | 143 |
| Foreign exchange remeasurement gain | -134 | 637 |
| Impairment of property, plant and equipment | 0 | 16,569 |
| Impairment of right-of-use assets | 0 | 0 |
| Change in fair value of contingent consideration | 0 | 0 |
| Depreciation | 12 | 510 |
| Restructuring costs | 0 | 91 |
| In-process research and development expenses | 0 | 10,000 |
| Accretion on invested securities | -111 | 181 |
| Non-cash interest expense | 193 | 405 |
| Change in fair value of derivative financial instrument | 0 | 0 |
| Loss on disposals of property and equipment | 0 | 0 |
| Prepaid expenses and other current assets | 897 | -5,830 |
| Other long-term assets | -2,787 | 2,442 |
| Accrued rent receivable | 3,093 | - |
| Accounts payable | 403 | -139 |
| Operating lease liabilities | -51 | -1,510 |
| Accrued expenses and other current liabilities | 1,592 | -3,168 |
| Net cash used in operating activities | -10,557 | -18,986 |
| Purchase of marketable securities | 6,558 | 76,907 |
| Maturities of marketable securities | 25,000 | 85,700 |
| Cash received from held for sale assets | 5 | 418 |
| Acquired in-process research and development | 10,000 | - |
| Purchase of derivative financial instrument | 0 | - |
| Net cash provided by investing activities | 8,447 | 9,211 |
| Proceeds from at-the-market offering, net of 0.3 million in issuance costs | 0 | 6,611 |
| Proceeds from exercise of stock options | 378 | 475 |
| Loan agreement closing costs | 0 | 172 |
| Net cash provided by financing activities | 378 | 6,914 |
| Net decrease in cash, cash equivalents and restricted cash | -1,732 | -2,861 |
| Effect of exchange rate changes on cash | 39 | - |
| Cash and cash equivalents at beginning of period | 10,635 | - |
| Cash and cash equivalents at end of period | 6,081 | - |
Instil Bio, Inc. (TIL)
Instil Bio, Inc. (TIL)